- Rating
- 4
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 3
- Soundness
- 3
Read review
Paper summary
This paper addresses the challenge of heterogeneous tool failures in medical AI agents by proposing Collaborative Synergy Reinforcement Learning (CSRL). The authors argue that disagreement among external diagnostic tools is not merely a source of uncertainty, but a valuable signal for exploiting case-level complementarity. This paper introduces the Single-Oracle risk gap, and guided by this metric, CSRL employs a GRPO-based optimization framework equipped with three key mechanisms: a Brier reward for probabilistic risk minimization, an override reward for disagreement-aware conflict resolution, and Entropy-Guided Sampling (EGS) to prioritize high-disagreement training cases.
Critical strengths
- The paper is well-organized. This proposed method actively exploits the complementarity and disagreement among imperfect tools. This is highly relevant for high-stakes domains like healthcare.
- The integration of the Brier reward, override reward, and EGS is logically sound. The authors provide theoretical propositions proving that maximizing these rewards aligns with minimizing prediction risk and enlarging the synergy risk gap.
- The method is evaluated across diverse datasets, tasks, and policy model scales. The inclusion of detailed ablation studies and multi-seed robustness analysis strengthens the validity of the effectiveness of the proposed method.
Critical weaknesses
- The effectiveness of CSRL fundamentally relies on the premise that the available tools have heterogeneous failure modes. If a predefined tool pool consists of models with highly correlated errors, the Single-Oracle risk gap shrinks, limiting the potential for synergistic gains. The paper assumes a well-curated tool pool but does not deeply address how to select or construct such a pool dynamically. In addition, many medical scenarios lacks the effective tools, which may also limit the applicability of this method.
- As acknowledged in the Ethics Statement, the evaluation is strictly retrospective on existing benchmarks. The actual clinical safety, robustness compared to real-world data. The authors are encouraged to train on internal trajectories and test on external real-world clinical cases.
Questions for authors
NA